Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,982 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06859762RecruitingPhase 1
YL217 for advanced solid tumors (first-in-human)
This study tests a new drug, YL217, for people with advanced solid tumors. It is a first-in-human trial, meaning this drug has not been tested in people before, and aims to see if it is safe and how well it works.
Phoenix, ArizonaAges 18 years+ - NCT06839560RecruitingPhase 2
Immunotherapy plus chemotherapy and radiation for advanced breast cancer with brain metastases
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06783647RecruitingPhase 2
LBL-024 combo for advanced solid tumors (NSCLC)
This trial tests a new drug combination for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if adding LBL-024 to other treatments can help shrink tumors or slow their growth.
Hefei, AnhuiAges 18–75 - NCT06716138RecruitingPhase 1
ANS03 for solid tumors with ROS1 or NTRK changes
This trial tests a new drug called ANS03 for people with certain genetic changes (ROS1 or NTRK) in their solid tumors. The goal is to see if ANS03 can shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06736704RecruitingPhase 1/Phase 2
Study of SNV4818 for advanced solid tumors with PIK3CA mutation
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT07111455Recruiting
Oral bacteria changes with chemoimmunotherapy for mouth cancer
This study is testing whether a combination of chemotherapy and immunotherapy before surgery can help treat advanced oral cancer. Researchers will also look at how the cancer changes the bacteria in your mouth.
Guangzhou, GuangdongAges 18–80 - NCT06794229RecruitingPhase 2
Zanzalintinib plus nivolumab before surgery for advanced kidney cancer
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT06618664RecruitingPhase 3
New triple combo vs standard therapy for advanced liver cancer
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
Hefei, AnhuiAges 18 years+ - NCT06672523RecruitingPhase 1
Study of a new drug for advanced solid tumors with MTAP deletion
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
BudapestAges 18 years+ - NCT06662760RecruitingPhase 1
TQB3002 for advanced cancers when standard treatments fail
This trial tests an experimental oral drug called TQB3002 for people with advanced solid tumors who have run out of standard options. Researchers are learning the best dose and how safe it is, with the hope of controlling or shrinking the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06632574RecruitingPhase 1
Paclitaxel liposomes via artery for advanced solid tumors
This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.
NanjingAges 18 years+ - NCT06694480RecruitingPhase 1
Study of FID-022 for advanced solid tumors
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
Los Angeles, CaliforniaAges 18 years+ - NCT06649292RecruitingPhase 3
Study of SHR-A1904 for gastric cancer with CLDN18.2
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Guangzhou, GuangdongAges 18–75 - NCT06644287Recruiting
PET scan to track immunotherapy response in advanced sarcoma
This trial uses a special PET scan called 68Ga-grazytracer to see how well your soft tissue sarcoma responds to immunotherapy treatment. It may help doctors understand if the treatment is working.
Shanghai, Shanghai MunicipalityAges 6–80 - NCT06550921Recruiting
Ablation plus lenvatinib and immunotherapy for advanced liver cancer
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
Beijing, None SelectedAges 18–75 - NCT06653452Recruiting
PET/MRI for rectal cancer treatment response
This study uses a special scan called PET/MRI to see how well treatment works for locally advanced rectal cancer before surgery. It may help doctors choose the best treatment plan for you.
Beijing, Beijing MunicipalityAges 18–75 - NCT06527300RecruitingPhase 2
Study of NHWD-870 for advanced NUT cancer
This trial tests a new drug called NHWD-870 for people with NUT cancer (a rare cancer linked to a gene change). The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
ChongqingAges 12–75 - NCT06439589RecruitingPhase 1/Phase 2
Drug combo for advanced solid tumors
This trial tests a new combination of two drugs (HRS2398 and Adebrelimab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Zhengzhou, HenanAges 18–75 - NCT06426680RecruitingPhase 1
Study of ILB-3101 for advanced solid tumors
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
ShanghaiAges 18–80 - NCT06464055RecruitingPhase 1/Phase 2
A study of GQ1010 for advanced solid tumors
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
BeijingAges 18 years+ - NCT06470217RecruitingPhase 2
Study of tirilizumab plus chemo for advanced oral cancer
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06384352RecruitingPhase 1
Study of YL211 for advanced solid tumors
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Aurora, ColoradoAges 18 years+ - NCT06400485RecruitingEarly Phase 1
Testing AMT-676 for advanced solid tumors
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Huntersville, North CarolinaAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,982 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.